365. Aerosol Delivery of an Enhanced Helper-Dependent Adenovirus Formulation to Rabbit Lung Using an Intratracheal Catheter

Koehler, David R.; Frndova, Helena; Leung, Kitty; Louca, Emily; Palmer, Donna; Ng, Philip; McKerlie, Colin; Cox, Peter; Coates, Allan L.; Hu, Jim
June 2005
Molecular Therapy;Jun2005, Vol. 11, p142
Academic Journal
An abstract of the article "Aerosol Delivery of an Enhanced Helper-Dependent Adenovirus Formulation to Rabbit Lung Using an Intratracheal Catheter," by David R. Koehler, Helena Frndova, Kitty Leung, Emily Louca, Donna Palmer, Philip Ng, Colin McKerlie, Peter Cox, and Allan L. Coates is presented.


Related Articles

  • Tumour angiogenesis as a target for adenoviral mediated antisense gene therapy in human prostate cancer. Wood, C G // Prostate Cancer & Prostatic Diseases;2000 Supplement 1, Vol. 3 Issue 4, pS43 

    Presents information on the development of an adenoviral mediated gene therapy strategy that targets tumor cell production of factors important in the angiogenic cascade. Reduction in tumor cell production; Utilization of reverse transcriptase-polymerase chain reaction.

  • Hide and seek. Le Page, Michael // New Scientist;04/28/2001, Vol. 170 Issue 2288, p11 

    Discusses the use of adenoviruses to sneak past the immune system and deliver missing genes to people with disorders. Process used to deliver genes; Problem with using adenoviruses for gene therapy; Result of using gene therapy to treat people with cystic fibrosis.

  • Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. Martinet, Olivier; Ermekova, Vanadyia; Martinet, O; Ermekova, V; Qiao, J Q; Sauter, B; Mandeli, J; Chen, L; Chen, S H // JNCI: Journal of the National Cancer Institute;06/07/2000, Vol. 92 Issue 11, p931 

    Background: The success of immunomodulatory cancer therapy is frequently hampered by the transient nature of the antitumor immune response. We have shown previously in a mouse model that interleukin 12 (IL-12) generates a strong natural killer (NK) cell-mediated antitumor response...

  • Adenoviral Vectors for Cancer Gene Therapy. Wenli Zhao, S.; Kobayashi, Masanobu; Hosokawa, Masuo; Seth, Prem // Current Genomics;Jun2002, Vol. 3 Issue 3, p163 

    Cancer gene therapy is considered a very viable approach for the treatment of cancer. The basic idea is to introduce the therapeutic gene, often in the form of a foreign cDNA, into the cancer or other appropriate target cells. For gene delivery purposes, several viral and non-viral vectors have...

  • Coacervate microspheres as carriers of recombinant adenoviruses. Kalyanasundaram, Subramanian; Feinstein, Sharon; Nicholson, Jennifer P; Leong, Kam W; Garver, Robert I // Cancer Gene Therapy;Mar1999, Vol. 6 Issue 2, p107 

    The therapeutic utility of recombinant adenoviruses (rAds) is limited in part by difficulties in directing the viruses to specific sites and by the requirement for bolus administration, both of which limit the efficiency of target tissue infection. As a first step toward overcoming these...

  • Development and application of adenoviral vectors for gene therapy of cancer. Zhang, Wei-Wei // Cancer Gene Therapy;Mar1999, Vol. 6 Issue 2, p113 

    For successful gene vaccination and therapy of cancer, it is essential to develop gene delivery vectors that can meet clinical and social requirements. The need for improved vectors was clearly manifested during the peak of the first wave of gene therapy. Adenoviral (Ad) vectors have recently...

  • Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters. Ebara, S; Shimura, S; Nasu, Y; Kaku, H; Kumon, H; Yang, G; Wang, J; Timme, T L; Aguilar-Cordova, E; Thompson, T C // Prostate Cancer & Prostatic Diseases;2002, Vol. 5 Issue 4, p316 

    Adenoviral vector delivery of the Herpes simplex virus thymidine kinase (HSV-tk) gene in combination with the prodrug ganciclovir (GCV) has been tested in phase I clinical trials for prostate cancer and found to exhibit a satisfactory toxicity profile. We have developed additional adenoviral...

  • Trials and tribulations.  // Nature Genetics;Mar2000, Vol. 24 Issue 3, p201 

    Comments on the debate about a clinical trial on gene therapy since the death of a man from a large dose of adenoviral vector. Trial of dose-escalation design; Increase of the levels of circulating factor IX; Reduction of the episodes of factor infusion.

  • Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Wang, Z.; Ma, H-I; Li, J.; Sun, L.; Zhang, J.; Xiao, X. // Gene Therapy;Dec2003, Vol. 10 Issue 26, p2105 

    Adeno-associated virus (AAV) is a promising gene vector based on a single-stranded (ss) DNA virus. Its transgene expression requires the conversion of ssDNA to double-stranded (ds) genome, a slow process responsible for the delayed transduction and occasional inefficiency. By mutating the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics